Commercialization: Page 25
-
PharmaVoice Team/PharmaVoice
SHOWCASE: Rare Disease: Rare Difficulties: Finding Cures and Tackling Costs
The day-to-day lives of people with rare diseases is often poorly understood. And those with rare diseases face many challenges. Whether it’s going to work or studying, completing daily tasks such as preparing meals and shopping, or simply managing their health, the impact disease has on patients...
By PharmaVoice Team • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Raising One Voice for the Millions Impacted by Rare Disease
Next-generation technologies in medicine have opened new doors for identifying rare diseases and developing better and more targeted rare disease treatments. Remarkable advancements in global research efforts have already made an impact on the lives of patients living with hundreds of rare diseas...
By Meredith Gartner • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Is the Rare Disease Business Model Here to Stay?
These days, the term “rare disease" is well ingrained in our everyday vernacular — but that hasn’t always been the case. The pharmaceutical industry paid little attention to developing new treatments for rare disease prior to the Reagan Administration’s implementation of the Orphan Drug Act (ODA)...
By Scott D. Hibbard • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
From Scientific Discovery to Real World Application: the "Future" of Medicine is Here
I vividly remember the day in February of 2001 when the nearly complete sequence of the human genome was first published. My cellular and molecular biology professor had unfolded a giant poster from the journal Nature and revealed those approximately 30,000 genes to our class. Amazingly, in less ...
By Jahda Hill • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Executive Perspective: A Fused Model for the Enterprise - A Conversation with Brian Williams
Winning in today’s digital era requires more than just apps and a website. Fusing an enterprise for success in the digital era requires companies to seamlessly collaborate across the enterprise and create a true strategic pathway for a better customer experience. Recently, Cognizant commissioned ...
By Brian Williams • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Red Zone: Disruptive Innovation: Questions for the C-Suite
It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote from Charles Darwin or a summary of his writings, this statement is perhaps the most profound scientific explanation of life itself, in all ...
By Srini Shankar • Feb. 1, 2019 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Artificial Intelligence Happy New Year. As we enter 2019, we take note of one of the major trends expected to impact all aspects of the life-sciences industry: artificial intelligence. In 2019, according to Forrester, AI solutions will continue to spread across the healthcare continuum thanks to ...
By Taren Grom • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Upfront
Medicinal Theater BioMarin Pharmaceutical and Believe Ltd. sponsored a first-of-its-kind theatrical production for teenagers with hemophilia. The musical, Hemophilia: The Musical, took place at New World Stages on Nov. 12, 2018. Before the performance, students participated in the Breaking Throug...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
HealthTech
Payers Use Healthtech to Improve Patient Outcomes, Lower Costs Trend Watch: Healthtech Mobile App Market Continues To Grow Payers Offer Free Wearables UnitedHealthcare, Aetna, and John Hancock have all implemented programs that offer free Apple Watches to customers, if they exercise daily. The la...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
Artificial Intelligence Key to Improving Healthcare Quality, Reducing Costs Trend Watch: AI Implications for Healthcare are Widespread Artificial Intelligence (AI) is key to building a better healthcare future, according to a recent survey of 500 U.S. healthcare leaders on their attitudes and usa...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Last Word
Combating Opioid Addiction Sarah Akerman, M.D., Senior Medical Director at Alkermes, talks about the industry’s role in opioid use disorder. PV: What are some of the biggest issues around the current treatment system for addiction? Akerman: The current treatment system for opioid addiction is ina...
By Sarah Akerman • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence: Molecule to Market
The adoption of artificial intelligence (AI) is rapidly taking hold across global businesses, including the life-sciences industry. AI is typically defined as the ability of a machine to perform cognitive functions associated with human minds, such as perceiving, reasoning, learning, and problem ...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Social Media: A Strategic Approach: Key to Social Media Success
Data from the second quarter of 2018 show that Facebook had 2.23 billion monthly active users, while Twitter had 326 million active users in the third quarter of 2018. Consumers use social media for many reasons today, including to learn about a medicine or illness. The use of social media forums...
By PharmaVoice Team • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
2019 Social Media Trends for Pharma
In a relatively short period of time, social media has reshaped communication for consumers and healthcare professionals alike. No longer are users simply posting content and communicating amongst themselves — social channels are now dominated by media reaching specifically targeted audiences. Lo...
By Brandie Linfante • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Drug Pricing Transparency: Will it be Now or Never?
In the ongoing clash between pharma and the Trump administration over pricing issues, CMS proposed a rule last year that would require pharmaceutical companies to include the price of any drug that cost more than $35 a month in their television ads. PhRMA preempted the salvo with a voluntary pled...
By Robin Robinson • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Red Zone: To Gain Competitive Advantage, Learn Your ABCDs
Understanding and staying engaged with patients throughout their treatment and wellness journey is a primary focus of the entire life sciences industry. The benefits are clear: • Patients’ trust in the therapy and its ecosystem grows • Longitudinal data on patient progress provides evidence for v...
By Sriraman Nagarajan • Jan. 1, 2019 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The year ahead… As we come to the end of 2018, it’s important to pause and reflect on not just where we’ve been, but where we are going as an industry. In 2018, we saw continuing uncertainty in terms of the Affordable Care Act. We welcomed Alex Azar as the new Secretary of Health and Human Servic...
By Taren Grom • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Last Word
In Her Shoes: Understanding the Female Patient Experience Elizabeth Bolgiano, Executive VP, Chief Human Resources Officer at AMAG Pharmaceuticals, discusses the company’s efforts to imagine “walking a mile" in its female patients’ shoes as they seek care for sexual health-related conditions. PV: ...
By Elizabeth Bolgiano • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Advanced Diagnostics and Precision Medicine
Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Admi...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Creating Shared Value
Shared value was first introduced by Michael Porter and Marc Kramer in their Harvard Business Review article in 2011. Since then, multiple industries have assessed how to implement shared value into their business practices. In other industries, companies need to work hard to find a public good t...
By Taren Grom • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Genetic Testing and Data Privacy and Ownership
Genetic testing is a booming market. According to reports, as of April 2018 more than 15 million people had taken direct-to-consumer genetic tests, and with prices for autosomal DNA tests now costing less than $100, they have become very accessible. Companies such as 23andMe, Ancestry.com, and My...
By Kim Ribbink • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Innovative Product Launches
Increasing complexity in the market and pressure on managing costs already create many challenges when it comes to new drug launches. Add to that the intricacies of innovative and combination drugs and the speed at which they need to launch, and challenges multiply. However, this shifting environ...
By Robin Robinson • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Multistakeholder Commercial Models
In the coming years, pharma will mobilize around engaging and accommodating a multitude of stakeholders to generate a competitive advantage. Long gone are the days of targeting healthcare providers as the entire commercial strategy. Simplicity in commercialization no longer exists and has been re...
By Robin Robinson • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Rare Disease Innovation
It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gen...
By PharmaVoice Team • Nov. 15, 2018 -
PharmaVoice Team/PharmaVoice
Trend: Voice Assistants
Alexa, how will voice assistants impact the pharmaceutical commercial landscape in the next five years? Alexa is “not sure about that," but our experts have the answers as smart speakers and voice technology begin to penetrate not only healthcare, but the pharma commercialization process as well....
By Robin Robinson • Nov. 15, 2018
Previous
